Is there hope for HER2-positive colorectal cancer with Trastuzumab? A review of current evidence

Trastuzumab combinations are emerging as a promising therapeutic strategy for HER2-positive colorectal cancer. This review investigates the current clinical data on efficacy and safety. Clinical trials have shown encouraging results, with objective response rates (ORRs) ranging from 22.2 to 46% and complete remission achievable in some patients. Additionally, these combinations demonstrate potential for improved overall survival (OS). However, optimizing therapeutic strategies remains crucial. Future research should tailor treatment regimens based on tumor biology and individual patient characteristics. Investigating ctDNA genotyping as a reliable method for identifying responders and exploring the role of Rat Sarcoma Virus (RAS) mutations and other molecular markers are key areas for optimizing patient selection and treatment efficacy. Understanding resistance mechanisms is vital for developing combination therapies that overcome these pathways.

Authors

Institutions

Publication Details

Journal
Annals of Medicine and Surgery
Published
2025-11-25
DOI
https://doi.org/10.1097/ms9.0000000000004459
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Is there hope for HER2-positive colorectal cancer with Trastuzumab? A review of current evidence

Gbolahan Olatunji, Nitin Rao, Nicholas Aderinto, Emmanuel Kokori et al.
Annals of Medicine and Surgery
HER2/EGFR in Cancer Research
article

Is there hope for HER2-positive colorectal cancer with Trastuzumab? A review of current evidence

Gbolahan Olatunji, Nitin Rao, Nicholas Aderinto, Emmanuel Kokori, Oluwafemi Isaiah Ajimotokan, Chimezirim Ezeano, Joan Oluwadamilola Ajayi, Tejiri Napoleon, Michael Awoyinfa, Israel Charles Abraham, Ajayi Oluwatomisin Temidayo, Emmanuel Elorm Nortey-Adom, Sharon Aa-inir Karbo, Sulaimon Olaide Bukky
article en

Abstract

Trastuzumab combinations are emerging as a promising therapeutic strategy for HER2-positive colorectal cancer. This review investigates the current clinical data on efficacy and safety. Clinical trials have shown encouraging results, with objective response rates (ORRs) ranging from 22.2 to 46% and complete remission achievable in some patients. Additionally, these combinations demonstrate potential for improved overall survival (OS). However, optimizing therapeutic strategies remains crucial. Future research should tailor treatment regimens based on tumor biology and individual patient characteristics. Investigating ctDNA genotyping as a reliable method for identifying responders and exploring the role of Rat Sarcoma Virus (RAS) mutations and other molecular markers are key areas for optimizing patient selection and treatment efficacy. Understanding resistance mechanisms is vital for developing combination therapies that overcome these pathways.

Annals of Medicine and SurgeryVol. 88(1)
University of Ilorin (NG), Johns Hopkins University (US), Mid Cheshire Hospitals NHS Foundation Trust (GB), University of Lagos (NG), Johns Hopkins Bayview Medical Center (US), Babcock University (NG), East Cheshire NHS Trust (GB), Federal Medical Centre (NG), University of Nigeria Teaching Hospital (NG), Ladoke Akintola University of Technology (NG), Kharkiv National Medical University (UA)
Openalex Percentile: Top 46%
HER2/EGFR in Cancer Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.